Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Sartorius AG ST

Start price
Target price
Perf. (%)
€474.50
15.07.21
-
15.07.22
-30.56%
13.03.22

Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€61.80
08.03.21
-
08.03.22
-21.91%
09.03.22

buy
Drägerwerk AG & Co. KGaA ST

Start price
Target price
Perf. (%)
€61.80
08.03.21
-
08.03.22
-26.29%
09.03.22

buy
Fresenius Medical Care AG & Co KGaA ST

Start price
Target price
Perf. (%)
€57.94
01.03.21
-
01.03.22
-2.93%
02.03.22

buy
Vita 34 AG

Start price
Target price
Perf. (%)
€15.55
21.02.21
-
21.02.22
-25.08%
22.02.22

Very Future proof/growth oriented business model
Market Leader or Top 3
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€36.24
01.02.21
€40.00
01.02.22
1.56%
01.02.22

buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€38.44
27.01.21
€45.00
27.01.22
-4.29%
28.01.22

Could be worthwhile Investment >10% per year
buy
Drägerwerk AG & Co. KGaA ST

Start price
Target price
Perf. (%)
€67.80
23.01.21
€88.00
23.01.22
-26.99%
24.01.22

Fair valuation
Top 10 in its market
Future proof or reliable business model
Could be worthwhile Investment >10% per year
buy
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€71.80
23.01.21
€88.00
23.01.22
-30.36%
24.01.22

Market Leader or Top 3
Well known brand
Very Future proof/growth oriented business model
Revenue growth > 30% per year expected
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€4.14
09.01.22
-
09.01.23
-5.80%
23.01.22

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Eckert & Ziegler Strahlen- und Medizintechnik AG

Start price
Target price
Perf. (%)
€123.30
17.08.21
-
17.08.22
-27.01%
12.01.22

buy
Mediclin AG

Start price
Target price
Perf. (%)
€4.36
10.01.21
€6.00
10.01.22
-15.14%
11.01.22

EBIT growth >5% per year expected
positive Cash Flow expected
Top 10 in its market
Future proof or reliable business model
buy
Stratec SE

Start price
Target price
Perf. (%)
€122.40
30.12.20
€128.00
30.12.21
12.75%
31.12.21

Could be worthwhile Investment >10% per year
buy
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€76.10
09.07.21
-
09.07.22
-25.49%
05.12.21

buy
Vita 34 AG

Start price
Target price
Perf. (%)
€16.50
11.11.21
-
11.11.22
0.61%
12.11.21

Bio-Gate AG

Start price
Target price
Perf. (%)
€5.90
04.11.20
-
04.11.21
-32.20%
05.11.21

Growths faster than the competition
Few uniques
Dependend from some customers or products
Probably not worthwhile Investment
buy
M1 Kliniken AG

Start price
Target price
Perf. (%)
€9.44
06.08.20
€12.00
04.11.21
-12.08%
05.11.21

Could be worthwhile Investment >10% per year
Capable Management
Small cyclical dependencies
buy
Gerresheimer AG

Start price
Target price
Perf. (%)
€90.75
06.07.20
€80.00
04.11.21
-8.48%
05.11.21

buy
Gerresheimer AG

Start price
Target price
Perf. (%)
€59.40
01.04.20
€100.00
04.11.21
39.81%
05.11.21

Could be worthwhile Investment >10% per year
buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€42.80
02.03.20
-
04.11.21
-8.24%
05.11.21

Eckert & Ziegler Strahlen- und Medizintechnik AG

Start price
Target price
Perf. (%)
€38.20
12.09.19
€37.50
04.11.21
255.24%
05.11.21

buy
Carl Zeiss Meditec AG

Start price
Target price
Perf. (%)
€101.30
10.08.19
€169.00
04.11.21
83.17%
05.11.21

buy
Carl Zeiss Meditec AG

Start price
Target price
Perf. (%)
€87.10
05.05.19
€200.00
04.11.21
113.03%
05.11.21

Could be worthwhile Investment >10% per year
buy
Carl Zeiss Meditec AG

Start price
Target price
Perf. (%)
€67.50
27.07.18
€110.00
04.11.21
174.89%
05.11.21

buy
Fresenius SE & Co. KGaA

Start price
Target price
Perf. (%)
€34.41
09.11.20
€40.00
09.11.21
18.27%
02.11.21

Could be very worthwhile Investment >20% year
Market Leader or Top 3
Revenue growth >5% per year expected
EBIT growth >5% per year expected